Telix Pharmaceuticals buys ITM in US$1.65B deal
Full story: https://grafa.com/en/news/australia/telix-pharmaceuticals-buys-itm-in-us-1-65b-deal
-
Telix Pharmaceuticals agreed to combine with ITM Isotope Technologies in a transaction valued at US$1.65 billion on a cash-free, debt-free basis.
-
The deal requires Telix to issue approximately US$1.25 billion in equity to ITM shareholders.
-
The merger aims to secure supply chains for therapeutic isotopes and broaden global radiopharmaceutical production.
Telix Pharmaceuticals (ASX:TLX) announced a strategic agreement to merge with ITM Isotope Technologies Munich SE in a deal valued at US$1.65 billion on a cash-free, debt-free basis.
The transaction represents a major expansion compared to ITM’s US$273 million revenue generated in 2025.
Telix Managing Director and Group CEO Dr. Christian Behrenbruch said, “This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures.”
The acquisition enhances vertical integration and secures core therapeutic supply chains, according to the company.
Under the terms, ITM shareholders will receive approximately US$1.25 billion in Telix shares priced at US$11.84 each, alongside potential earn-outs of up to US$700 million tied to regulatory and milestone targets.
The transaction remains subject to Telix shareholder approval and customary closing conditions.
Following the announcement, the Telix Pharmaceuticals share price was down at $16.63.
ITM operates a global distribution network spanning over 65 countries and produces therapeutic radioisotopes, including lutetium-177.
The German-based target recorded a 40% compound annual growth rate in revenue between 2021 and 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
